The pipeline looks strong despite the setbacks The pharma giant's top line climbed by 4% in constant currency, still not that impressive, but a better performance. Revenue in 2022 increased by just 1% year over year to $28.5 billion.

dollar strengthened last year, which decreased the value of international sales for multinational companies. These dynamics partly explain its relatively unimpressive results in 2022, but there are other factors. However, the company's revenue in this segment declined in 2022, coming in at $2 billion, 10% lower than the previous fiscal year.Įli Lilly's COVID-19 antibody sales dropped by a substantially larger amount, 96% year over year, in the fourth quarter. The drugmaker developed several coronavirus antibodies from which it generated solid sales. Like those of many other companies, Eli Lilly's financial results have been affected by pandemic-related factors. It's essential to put the past couple of years in context.

Is Eli Lilly stock a buy, even close to its 52-week high? Eli Lilly's financial results should improve

Furthermore, Eli Lilly's fourth-quarter update was not great.ĭespite these issues, the company continues to beat the market. Both candidates failed to earn regulatory approval in the U.S. For instance, the company has encountered regulatory obstacles for two important pipeline candidates: potential Alzheimer's disease (AD) therapy donanemab and investigational ulcerative colitis medicine mirikizumab. This year hasn't been great for Eli Lilly ( LLY -0.15%), at least so far.

Lily morton rule breaker